Ancobon Side Effects
Generic Name: flucytosine
Note: This page contains information about the side effects of flucytosine. Some of the dosage forms included on this document may not apply to the brand name Ancobon.
Not all side effects for Ancobon may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.
For the Consumer
Applies to flucytosine: oral capsule, oral tablet
In addition to its needed effects, some unwanted effects may be caused by flucytosine (the active ingredient contained in Ancobon). In the event that any of these side effects do occur, they may require medical attention.
You should check with your doctor immediately if any of these side effects occur when taking flucytosine:More common
- Skin rash, redness, or itching
- sore throat and fever
- unusual bleeding or bruising
- unusual tiredness or weakness
- yellow eyes or skin
- hallucinations (seeing, hearing, or feeling things that are not there)
- increased sensitivity of skin to sunlight
Some of the side effects that can occur with flucytosine may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:More common
- Abdominal pain
- loss of appetite
- nausea or vomiting
- Dizziness or lightheadedness
For Healthcare Professionals
Applies to flucytosine: oral capsule
Gastrointestinal side effects have included nausea, emesis, abdominal pain, diarrhea, anorexia, dry mouth, duodenal ulcer, gastrointestinal hemorrhage, enterocolitis, and ulcerative colitis.[Ref]
Nausea is common at high doses, generally occurs in the first two weeks of therapy, and often resolves with time or temporary dose reduction. Diarrhea is often associated with cramps, occurs most frequently in the first two weeks of therapy, and frequently resolves with time or temporary dose reduction. One case has been reported of a patient on long-term therapy who developed diarrhea which did not resolve spontaneously. X-ray of the small bowel revealed ulceration and the ileocecal valve and distal ileum appeared edematous. Flucytosine was discontinued and the patient improved over the next two weeks.[Ref]
Some patients experience significant increases in liver function tests and may develop signs and symptoms of hepatitis. Liver function test abnormalities generally resolve after discontinuation of flucytosine (the active ingredient contained in Ancobon) [Ref]
Hepatic side effects have included jaundice, hepatic dysfunction, bilirubin elevation, increased hepatic enzymes, and acute hepatic injury including hepatic necrosis with possible fatal outcome in debilitated patients.[Ref]
Hematologic side effects have included anemia, agranulocytosis, aplastic anemia, eosinophilia, leukopenia, pancytopenia, thrombocytopenia, and fatal cases of bone marrow suppression.[Ref]
Bone marrow suppression may range from isolated leukopenia or thrombocytopenia to pancytopenia. Often there is just mild leukopenia or thrombocytopenia which does not require discontinuation of the drug. In most cases the suppression is reversible following discontinuation of flucytosine therapy, but at least one case of fatal, irreversible marrow failure has occurred.[Ref]
Photosensitivity has been reported in one case of a patient receiving long-term flucytosine (the active ingredient contained in Ancobon) The photosensitivity persisted for one year after completion of therapy.
A case of anaphylaxis has been reported. In that case, a patient who had hemophilia and AIDS was receiving flucytosine for oral candidiasis. Flucytosine therapy was started following 10 days of miconazole and the patient developed a fever, erythema, pruritus, tachycardia and hypotension requiring volume support. Rechallenge was attempted one week later with one tablet. The rechallenge resulted in the same signs and symptoms and ran a similar course.[Ref]
Hypersensitivity side effects have included allergic reactions. Rashes have been reported rarely. At least one case of photosensitivity has been reported, in addition to a case of anaphylaxis.[Ref]
Cardiovascular side effects have included cardiac arrest, myocardial toxicity, and ventricular dysfunction. Cardiac toxicity with ST elevation has been reported in a 34-year-old woman, with no previous history of heart disease, the day after completing a 2-day flucytosine (the active ingredient contained in Ancobon) therapy.[Ref]
A 34-year-old woman reported severe chest pain the day after completing a 2-day flucytosine therapy. Cardiac echography indicated septo-apico-lateral severe hypokinesia, with left ventricular ejection fraction less than 15%. Aggressive cardiac intensive care with positive inotropic agents, placement of an intra-aortic balloon pump counterpulsation, and milrinone along with continuous veno-venous hemodiafiltration were needed over the 2 weeks of hospitalization before restoration of her cardiovascular status. Patient has not shown further signs of heart problems during the 2 years since this event.[Ref]
Respiratory side effects have included dyspnea, chest pain, and respiratory arrest.[Ref]
Dermatologic side effects have included rash, pruritus, urticaria, photosensitivity, and Lyell's syndrome.[Ref]
Genitourinary side effects have included crystalluria.[Ref]
Renal side effects have included azotemia, creatinine and BUN elevation, and renal failure.[Ref]
Nervous system side effects have included ataxia, hearing loss, headache, paresthesia, parkinsonism, peripheral neuropathy, pyrexia, vertigo, sedation, and convulsions.[Ref]
Psychiatric side effects have included confusion, hallucinations, and psychosis.[Ref]
Metabolic side effects have included hypoglycemia.
Other side effects have included fatigue and weakness.[Ref]
1. Stamm AM, Diasio RB, Dismukes WE, et al "Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis." Am J Med 83 (1987): 236-42
2. Thompson GR 3rd, Cadena J, Patterson TF "Overview of antifungal agents." Clin Chest Med 30 (2009): 203-15, v
3. "Product Information. Ancobon (flucytosine)." Roche Laboratories, Nutley, NJ.
4. Bennett JE, Dismukes WE, Duma RJ, et al "A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis." N Engl J Med 301 (1979): 126-31
5. White CA, Traube J "Ulcerating enteritis associated with flucytosine therapy." Gastroenterology 83 (1982): 1127-9
6. Harder EJ, Hermans PE "Treatment of fungal infections with flucytosine." Arch Intern Med 135 (1975): 231-7
7. Record CO, Skinner JM, Sleight P, Speller DC "Candida endocarditis treated with 5-fluorocytosine." Br Med J 01/30/71 (1971): 262-4
8. Holdsworth SR, Atkins RC, Scott DF, Jackson R "Management of candida peritonitis by prolonged peritoneal lavage containing 5-fluorocytosine." Clin Nephrol 4 (1975): 157-9
9. Kauffman CA, Frame PT "Bone marrow toxicity associated with 5-fluorocytosine therapy." Antimicrob Agents Chemother 11 (1977): 244-7
10. Wise GJ, Goldberg P, Kozinn PJ, Nawabi IU "Agranulocytosis associated with flucytosine for urinary candidiasis." Urology 8 (1976): 490-1
11. Kotani S, Hirose S, Niiya K, et al "Anaphylaxis to flucytosine in a patient with AIDS." JAMA 260 (1988): 3275-6
12. Shelley WB, Sica PA Jr "Disseminate sporotrichosis of skin and bone cured with 5-fluorocytosine: photosensitivity as a complication." J Am Acad Dermatol 8 (1983): 229-35
13. Isetta C, Garaffo R, Bastian G, Jourdan J, Baudouy M, Milano G "Life-threatening 5-fluorouracil-like cardiac toxicity after treatment with 5-fluorocytosine." Clin Pharmacol Ther 67 (2000): 323-5
More about Ancobon (flucytosine)
Related treatment guides
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.